{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T13:12:29Z","timestamp":1790341949264,"version":"4.1.0"},"reference-count":38,"publisher":"Innovative Healthcare Institute","issue":"1","license":[{"start":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T00:00:00Z","timestamp":1698451200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,2,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>NUT carcinomas (NCs) are a group of rare tumors that can occur anywhere in the body and are defined by the fusion of the nuclear protein in testis (NUTM1) resulting in increased transcription of proto-oncogenes. NCs have a poor prognosis that varies according to the site of origin with an urgent need to develop new treatment strategies. Case reports on immunotherapy in pulmonary NC have been published, and bromodomain and extraterminal (BET) inhibitors have shown activity in NC in phase I\/II trials. We present the case of a 27-year-old woman with an unresectable sinonasal NC who had a sustained clinical response to both immunotherapy and BET inhibitor therapy. This is the first reported case of immunotherapy in sinonasal NC, and it highlights the different responses to a range of treatments including BET inhibitor therapy. This case supports the theory that NCs arising from different primary sites have differing prognoses.<\/jats:p>","DOI":"10.36401\/jipo-23-19","type":"journal-article","created":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T12:34:47Z","timestamp":1698496487000},"page":"67-72","source":"Crossref","is-referenced-by-count":8,"title":["Sustained Clinical Response to Immunotherapy Followed by BET Inhibitor in a Patient with Unresectable Sinonasal NUT Carcinoma"],"prefix":"10.36401","volume":"7","author":[{"given":"Harriet","family":"Herbison","sequence":"first","affiliation":[{"name":"1 Department of Medical Oncology, Monash Health, Clayton, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sidney","family":"Davis","sequence":"additional","affiliation":[{"name":"2 Department of Radiation Oncology, The Alfred Hospital, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Nickless","sequence":"additional","affiliation":[{"name":"3 Department of Anatomical Pathology, Cabrini Pathology, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Haydon","sequence":"additional","affiliation":[{"name":"4 Department of Medical Oncology, The Alfred Hospital, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malaka","family":"Ameratunga","sequence":"additional","affiliation":[{"name":"4 Department of Medical Oncology, The Alfred Hospital, Melbourne, Victoria, Australia"},{"name":"5 Central Clinical School, Monash University, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"22027","published-online":{"date-parts":[[2024,2,5]]},"reference":[{"key":"2024020423514943900_i2590-017X-7-1-67-b01","doi-asserted-by":"crossref","first-page":"860830","DOI":"10.3389\/fonc.2022.860830","article-title":"NUT carcinoma: clinicopathologic features, molecular genetics and epigenetics","volume":"12","author":"Moreno","year":"2022","journal-title":"Front Oncol"},{"key":"2024020423514943900_i2590-017X-7-1-67-b02","doi-asserted-by":"crossref","first-page":"5773","DOI":"10.1158\/1078-0432.CCR-12-1153","article-title":"Clinicopathologic features and long-term outcomes of NUT midline carcinoma","volume":"18","author":"Bauer","year":"2012","journal-title":"Clin Cancer Res"},{"key":"2024020423514943900_i2590-017X-7-1-67-b03","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.3390\/cancers14174079","article-title":"BMS-986158, a small molecule inhibitor of the bromodomain and extraterminal domain proteins, in patients with selected advanced solid tumors: results from a phase 1\/2a trial","volume":"14","author":"Hilton","year":"2022","journal-title":"Cancers"},{"key":"2024020423514943900_i2590-017X-7-1-67-b04","doi-asserted-by":"crossref","first-page":"pkz093","DOI":"10.1093\/jncics\/pkz093","article-title":"Phase 1 study of molibresib (GSK525762), a bromodomain and extra-terminal domain protein inhibitor, in NUT carcinoma and other solid tumors","volume":"4","author":"Piha-Paul","year":"2019","journal-title":"JNCI Cancer Spectr"},{"key":"2024020423514943900_i2590-017X-7-1-67-b05","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1038\/s41416-020-01077-z","article-title":"First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours","volume":"123","author":"Ameratunga","year":"2020","journal-title":"Br J Cancer"},{"key":"2024020423514943900_i2590-017X-7-1-67-b06","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1200\/JCO.2018.78.2292","article-title":"Phase Ib trial with birabresib, a small-molecule inhibitor of bromodomain and extraterminal proteins, in patients with selected advanced solid tumors","volume":"36","author":"Lewin","year":"2018","journal-title":"J Clin Oncol"},{"key":"2024020423514943900_i2590-017X-7-1-67-b07","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/s41416-020-01180-1","article-title":"A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma","volume":"124","author":"Shapiro","year":"2021","journal-title":"Br J Cancer"},{"key":"2024020423514943900_i2590-017X-7-1-67-b08","doi-asserted-by":"crossref","first-page":"690115","DOI":"10.3389\/fonc.2021.690115","article-title":"Immunotherapy and targeting the tumor microenvironment: current place and new insights in primary pulmonary NUT carcinoma","volume":"11","author":"Li","year":"2021","journal-title":"Front Oncol"},{"key":"2024020423514943900_i2590-017X-7-1-67-b09","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s13023-020-01449-x","article-title":"Clinical features, treatment, and survival outcome of primary pulmonary NUT midline carcinoma","volume":"15","author":"Xie","year":"2020","journal-title":"Orphanet J Rare Dis"},{"key":"2024020423514943900_i2590-017X-7-1-67-b10","doi-asserted-by":"crossref","first-page":"e665","DOI":"10.1016\/j.cllc.2020.10.016","article-title":"Prolonged disease control on nivolumab for primary pulmonary NUT carcinoma","volume":"22","author":"Davis","year":"2021","journal-title":"Clin Lung Cancer"},{"key":"2024020423514943900_i2590-017X-7-1-67-b11","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1093\/annonc\/mdx299","article-title":"Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II\u2013III trial","volume":"28","author":"Ghi","year":"2017","journal-title":"Ann Oncol"},{"key":"2024020423514943900_i2590-017X-7-1-67-b12","doi-asserted-by":"crossref","first-page":"pkz094","DOI":"10.1093\/jncics\/pkz094","article-title":"An anatomical site and genetic-based prognostic model for patients with nuclear protein in testis (NUT) midline carcinoma: analysis of 124 patients","volume":"4","author":"Chau","year":"2020","journal-title":"JNCI Cancer Spectr"},{"key":"2024020423514943900_i2590-017X-7-1-67-b13","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1158\/1078-0432.CCR-22-0591","article-title":"Report of the first international symposium on NUT carcinoma","volume":"28","author":"French","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2024020423514943900_i2590-017X-7-1-67-b14","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1097\/PAS.0b013e318198d666","article-title":"Diagnosis of NUT midline carcinoma using a NUT-specific monoclonal antibody","volume":"33","author":"Haack","year":"2009","journal-title":"Am J Surg Pathol"},{"key":"2024020423514943900_i2590-017X-7-1-67-b15","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1097\/PAS.0000000000001021","article-title":"NUTM1 gene fusions characterize a subset of undifferentiated soft tissue and visceral tumors","volume":"42","author":"Dickson","year":"2018","journal-title":"Am J Surg Pathol"},{"key":"2024020423514943900_i2590-017X-7-1-67-b16","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s00405-018-4882-y","article-title":"Patterns of care and impact of prognostic factors in the outcome of NUT midline carcinoma: a systematic review and individual patient data analysis of 119 cases","volume":"275","author":"Giridhar","year":"2018","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"2024020423514943900_i2590-017X-7-1-67-b17","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1080\/08880018.2017.1363839","article-title":"Pediatric NUT-midline carcinoma: therapeutic success employing a sarcoma based multimodal approach","volume":"34","author":"Storck","year":"2017","journal-title":"Pediatr Hematol Oncol"},{"key":"2024020423514943900_i2590-017X-7-1-67-b18","doi-asserted-by":"crossref","first-page":"e707","DOI":"10.1097\/MPH.0000000000001865","article-title":"NUT carcinoma without upfront surgical resection: a case report","volume":"43","author":"Leeman","year":"2021","journal-title":"J Pediatr Hematol Oncol"},{"key":"2024020423514943900_i2590-017X-7-1-67-b19","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1002\/pbc.20755","article-title":"Successful treatment of a child with t(15;19)-positive tumor","volume":"49","author":"Mertens","year":"2007","journal-title":"Pediatr Blood Cancer"},{"key":"2024020423514943900_i2590-017X-7-1-67-b20","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/S1470-2045(20)30737-3","article-title":"Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial","volume":"22","author":"Lee","year":"2021","journal-title":"Lancet Oncol"},{"key":"2024020423514943900_i2590-017X-7-1-67-b21","doi-asserted-by":"crossref","first-page":"S1399","DOI":"10.1016\/j.annonc.2022.08.029","article-title":"LBA5 primary results of the phase III KEYNOTE-412 study: pembrolizumab (pembro) with chemoradiation therapy (CRT) vs placebo plus CRT for locally advanced (LA) head and neck squamous cell carcinoma (HNSCC)","volume":"33","author":"Machiels","year":"2022","journal-title":"Ann Oncol"},{"key":"2024020423514943900_i2590-017X-7-1-67-b22","doi-asserted-by":"crossref","first-page":"6361","DOI":"10.1007\/s00432-023-04621-5","article-title":"Clinical and molecular features of pulmonary NUT carcinoma characterizes diverse responses to immunotherapy, with a pathologic complete response case","volume":"149","author":"Chen","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"2024020423514943900_i2590-017X-7-1-67-b23","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1089\/ct.2021;33.38-47","article-title":"NUT carcinoma of the thyroid: an unusual case with a complete response to treatment","volume":"33","author":"Kuo","year":"2021","journal-title":"Clin Thyroid"},{"key":"2024020423514943900_i2590-017X-7-1-67-b24","doi-asserted-by":"crossref","first-page":"101184","DOI":"10.1016\/j.tranon.2021.101184","article-title":"Genomic profiling of solid tumors harboring BRD4-NUT and response to immune checkpoint inhibitors","volume":"14","author":"Riess","year":"2021","journal-title":"Transl Oncol"},{"key":"2024020423514943900_i2590-017X-7-1-67-b25","doi-asserted-by":"crossref","first-page":"778296","DOI":"10.3389\/fonc.2021.778296","article-title":"Primary thyroid NUT carcinoma with high PD-L1 expression and novel massive IGKV gene fusions: a case report with treatment implications and literature review","volume":"11","author":"Zhou","year":"2022","journal-title":"Front Oncol"},{"key":"2024020423514943900_i2590-017X-7-1-67-b26","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ejca.2020.02.038","article-title":"Tumour mutational burden as a biomarker for immunotherapy: current data and emerging concepts","volume":"131","author":"Fumet","year":"2020","journal-title":"Eur J Cancer"},{"key":"2024020423514943900_i2590-017X-7-1-67-b27","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.molcel.2008.01.018","article-title":"The double bromodomain proteins Brd2 and Brd3 couple histone acetylation to transcription","volume":"30","author":"LeRoy","year":"2008","journal-title":"Mol Cell"},{"key":"2024020423514943900_i2590-017X-7-1-67-b28","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1128\/MCB.01341-10","article-title":"The Brd4 extraterminal domain confers transcription activation independent of pTEFb by recruiting multiple proteins, including NSD3","volume":"31","author":"Rahman","year":"2011","journal-title":"Mol Cell Biol"},{"key":"2024020423514943900_i2590-017X-7-1-67-b29","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1101\/gad.267583.115","article-title":"The oncogenic BRD4-NUT chromatin regulator drives aberrant transcription within large topological domains","volume":"29","author":"Alekseyenko","year":"2015","journal-title":"Genes Dev"},{"key":"2024020423514943900_i2590-017X-7-1-67-b30","doi-asserted-by":"crossref","first-page":"621093","DOI":"10.3389\/fphar.2020.621093","article-title":"Safety and efficacy of bromodomain and extra-terminal inhibitors for the treatment of hematological malignancies and solid tumors: a systematic study of clinical trials","volume":"11","author":"Sun","year":"2020","journal-title":"Front Pharmacol"},{"key":"2024020423514943900_i2590-017X-7-1-67-b31","doi-asserted-by":"crossref","first-page":"pkz092","DOI":"10.1093\/jncics\/pkz092","article-title":"How much can we bet on activity of BET inhibitors beyond NUT\u2013midline carcinoma","volume":"4","author":"Martin-Romano","year":"2019","journal-title":"JNCI Cancer Spectr"},{"key":"2024020423514943900_i2590-017X-7-1-67-b32","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1101\/gad.315648.118","article-title":"Genetic modifiers of the BRD4-NUT dependency of NUT midline carcinoma uncovers a synergism between BETis and CDK4\/6is","volume":"32","author":"Liao","year":"2018","journal-title":"Genes Dev"},{"key":"2024020423514943900_i2590-017X-7-1-67-b33","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1158\/1535-7163.MCT-20-0087","article-title":"Combined targeting of the BRD4\u2013NUT\u2013p300 axis in NUT midline carcinoma by dual selective bromodomain inhibitor, NEO2734","volume":"19","author":"Morrison-Smith","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"2024020423514943900_i2590-017X-7-1-67-b34","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/s41416-022-01815-5","article-title":"Therapeutic impact of BET inhibitor BI 894999 treatment: backtranslation from the clinic","volume":"127","author":"Tontsch-Grunt","year":"2022","journal-title":"Br J Cancer"},{"key":"2024020423514943900_i2590-017X-7-1-67-b35","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1158\/0008-5472.CAN-10-3513","article-title":"Differentiation of NUT midline carcinoma by epigenomic reprogramming","volume":"71","author":"Schwartz","year":"2011","journal-title":"Cancer Res"},{"key":"2024020423514943900_i2590-017X-7-1-67-b36","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/pbc.25350","article-title":"Histone deacetylase inhibitor for NUT midline carcinoma","volume":"62","author":"Maher","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"2024020423514943900_i2590-017X-7-1-67-b37","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1158\/1541-7786.MCR-21-0259","article-title":"Chemical screen identifies diverse and novel histone deacetylase inhibitors as repressors of NUT function: implications for NUT carcinoma pathogenesis and treatment","volume":"19","author":"Shiota","year":"2021","journal-title":"Mol Cancer Res"},{"key":"2024020423514943900_i2590-017X-7-1-67-b38","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1128\/MCB.05413-11","article-title":"Structural basis and specificity of acetylated transcription factor GATA1 recognition by BET family bromodomain protein Brd3","volume":"31","author":"Gamsjaeger","year":"2011","journal-title":"Mol Cell Biol"}],"container-title":["Journal of Immunotherapy and Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/meridian.allenpress.com\/innovationsjournals-JIPO\/article-pdf\/7\/1\/67\/3324484\/i2590-017x-7-1-67.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/meridian.allenpress.com\/innovationsjournals-JIPO\/article-pdf\/7\/1\/67\/3324484\/i2590-017x-7-1-67.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T17:48:25Z","timestamp":1765475305000},"score":1,"resource":{"primary":{"URL":"https:\/\/innovationsjournals-jipo.kglmeridian.com\/view\/journals\/jipo\/7\/1\/article-p67.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,1]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,2,5]]},"published-print":{"date-parts":[[2024,2,1]]}},"URL":"https:\/\/doi.org\/10.36401\/jipo-23-19","relation":{},"ISSN":["2590-017X","2666-2345"],"issn-type":[{"value":"2590-017X","type":"electronic"},{"value":"2666-2345","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2,1]]}}}